FDAnews Drug Daily Bulletin
Feb. 16, 2005 | Vol. 2 No. 33
GlaxoSmithKline (GSK) was recently hit with an FDA warning letter for presenting a misleading promotional panel for its cardiovascular drug Coreg at an industry conference last June.
More light may soon shine on the financial deals made between drugmakers and pharmaceutical benefit managers (PBMs), as Maine moves closer to implementing its PBM disclosure law.
GlaxoSmithKline (GSK) has agreed to pay $65 million to settle a class action antitrust lawsuit filed over its antidepressant Paxil.
Barr Laboratories has filed a lawsuit against the FDA in federal court to obtain 180 days of marketing exclusivity for its generic version of Aventis' Allegra-D allergy drug.
Seattle Genetics has announced that CuraGen has exercised its option to designate a second antigen target under the parties' existing antibody-drug conjugate (ADC) collaboration, triggering a $1 million payment to Seattle Genetics.
Cellular Genomics (CGI), a chemical genetics based drug discovery and development company, has announced the completion of a key performance milestone in its joint kinase discovery program with Serono.
Australia's adult stem cell company, Mesoblast, has announced that it had signed an agreement for production of specialized adult stem cells, known as Mesenchymal Precursor Cells (MPCs), to be used in human pilot clinical trials in patients with orthopedic and cardiovascular diseases.
Scientists at SIGA Technologies and privately held TransTech Pharma (TTP) announced the receipt of a $2.7 million challenge grant from the National Institutes of Health (NIH) to support the development of protease inhibitors to treat orthopoxvirus infections, such as smallpox and monkeypox.
The Indian pharmaceutical sector has begun its seismic shake-up following the introduction of new laws granting patent protection to medicines on Jan. 1.
Vertex Pharmaceuticals and Avalon Pharmaceuticals have announced that they have entered into a licensing agreement for the development of the investigational agent VX-944 in oncology indications.
Fuso Pharmaceutical Industries has announced that it has concluded a collaborative research agreement with HuBit genomix, a Tokyo-based biotech firm.
Swiss pharmaceuticals giant Novartis is in talks to buy German generic-drugs maker Hexal and two of its subsidiaries for up to €4.5 billion (R35.6 billion), the daily Die Welt reported on Tuesday.
CoTherix has announced that the underwriters of its follow-on offering have exercised their over-allotment option to purchase an additional 250,000 shares of common stock from CoTherix to be offered at the public offering price of $8.90 per share.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.